DOCSLIB.ORG

Dipeptide Derivatives As Growth Hormone Secretagogues

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Dipeptide Derivatives As Growth Hormone Secretagogues Europäisches Patentamt *EP001002802B1* (19) European Patent Office Office européen des brevets (11) EP 1 002 802 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.7: C07K 5/03, C07K 5/062, of the grant of the patent: A01K 67/00, A61K 38/05, 08.12.2004 Bulletin 2004/50 A61K 38/06, A61P 5/06 (21) Application number: 99309036.4 (22) Date of filing: 12.11.1999 (54) Dipeptide derivatives as growth hormone secretagogues Dipeptide zur Förderung der Sekretion des Wachstumshormons Dipéptides comme secretagogues d’hormone de croissance (84) Designated Contracting States: (74) Representative: AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU Simpson, Alison Elizabeth Fraser et al MC NL PT SE Urquhart-Dykes & Lord LLP 30 Welbeck Street (30) Priority: 20.11.1998 US 109219 P London W1G 8ER (GB) (43) Date of publication of application: (56) References cited: 24.05.2000 Bulletin 2000/21 WO-A-96/35713 WO-A-96/38471 WO-A-97/24369 WO-A-98/58947 (73) Proprietor: Pfizer Products Inc. Groton, Connecticut 06340 (US) Remarks: The file contains technical information submitted (72) Inventors: after the application was filed and not included in this • Griffith, David Andrew specification Old Saybrook, Connecticut 06475 (US) • Bronk, Brian Scott Gales Ferry, Connecticut 06335 (US) Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention). EP 1 002 802 B1 Printed by Jouve, 75001 PARIS (FR) EP 1 002 802 B1 Description [0001] This invention relates to dipeptide compounds which are growth hormone secretagogues and are useful for the treatment and prevention of osteoporosis and/or frailty, insulin resistance in mammals, congestive heart failure, 5 obesity, accelerating bone fracture repair and accelerating wound repair. Background of the Invention [0002] Growth hormone (GH), which is secreted from the pituitary gland, stimulates growth of all tissues of the body 10 that are capable of growing. In addition, growth hormone is known to have the following basic effects on the metabolic processes of the body: 1. Increased rate of protein synthesis in substantially all cells of the body; 2. Decreased rate of carbohydrate utilization in cells of the body; and 15 3. Increased mobilization of free fatty acids and use of fatty acids for energy. [0003] Deficiency in growth hormone results in a variety of medical disorders. In children, it causes dwarfism. In adults, the consequences of acquired GH deficiency include profound reduction in lean body mass and concomitant increase in total body fat, particularly in the truncal region. Decreased skeletal and cardiac muscle mass and muscle 20 strength lead to a significant reduction in exercise capacity. Bone density is also reduced. Administration of exogenous growth hormone has been shown to reverse many of the metabolic changes. Additional benefits of therapy have in- cluded reduction in LDL cholesterol and improved psychological well-being. This is described in U.S. Patent No. 60/050,764. [0004] International Patent Publication No. WO97/24369 also discloses the use of dipeptide compounds as growth 25 hormone secretagogues for the treatment or prevention of osteoporosis. [0005] International Patent Publication No. WO96/38471 relates to dipeptide compounds which are growth hormone releasing peptide mimetics and are useful for the treatment or prevention of osteoporosis. [0006] International Patent Publication No. WO96/35713 relates to dipeptide compounds which are growth hormone releasing mimetics and are useful in the treatment or prevention of osteoporosis. 30 Summary of the Invention [0007] The present invention provides novel chemical compounds of the following Formula I 35 40 or a pharmaceutically acceptable salt or prodrug thereof, 45 wherein: HET is a heterocyclic moiety selected from the group consisting of 50 55 2 EP 1 002 802 B1 5 10 15 20 25 e is 0 or 1; n and w are each independently 0, 1, or 2, provided that w and n cannot both be 0 at the same time; Y is oxygen or sulfur; 2 R is selected from the group consisting of hydrogen, fluoro, and (C1-C5)alkyl optionally substituted with 1-5 halo groups; 30 2A 6 6 6 6 R is selected from the group consisting of hydrogen, SX ,OX , -N(X )(X ), (C1-C8)alkyl, -(C0-C3)alkyl-(C1-C7) 1 cycloalkyl, and -(C0-C3)alkyl-A , where the alkyl groups and the cycloalkyl groups are optionally substituted with 6 6 6 6 6 1 6 hydroxy, thio, C(O)OX , C(O)N(X )(X ), SO2N(X )(X ), S(O)m(C1-C6)alkyl, C(O)A , C(O)(X ), CN or 1-5 halo groups; Q is a covalent bond or CR9R10; 35 Z is C=O, C=S or S(O)2; 2B 1 1 R is hydrogen, (C1-C8)alkyl, (C0-C3)alkyl-(C3-C8)cycloalkyl, -(C1-C4)alkyl-A or A ; where the alkyl groups and the cycloalkyl groups in the definition of R2B are optionally substituted with hydroxyl, C(O)OX6, -C(O)N(X6)(X6), 6 6 1 6 -N(X )(X ), -S(O)m(C1-C6)alkyl, C(O)A , -C(O)(X ), CF3, CN or 1, 2 or 3 halogen; 1 6 6 6 1 6 1 R is hydrogen, -CN, -(CH2)qN(X )C(O)X , -(CH2)qN(X )C(O)(CH2)t-A , -(CH2)qN(X )S(O)2(CH2)t-A , -(CH2)qN 40 6 6 6 6 1 6 6 6 6 6 (X )S(O)2X , -(CH2)qN(X )C(O)N(X )(CH2)tA , -(CH2)qN(X )C(O)N(X )(X ), -(CH2)qC(O)N(X )(X ), -(CH2)qC(O) 6 1 6 1 6 6 1 N(X )(CH2)t-A , -(CH2)qC(O)OX , -(CH2)qC(O)O(CH2)t-A , -(CH2)qOX , -(CH2)qOC(O)X ,-(CH2)qOC(O)(CH2)tA , 6 1 6 6 6 1 6 -(CH2)qOC(O)N(X )(CH2)t-A , -(CH2)qOC(O)N(X )(X ), -(CH2)qC(O)X , -(CH2)qC(O)(CH2)t-A , -(CH2)qN(X )C(O) 6 6 6 6 6 1 1 OX , -(CH2)qN(X )S(O)2N(X )(X ), -(CH2)qS(O)mX , -(CH2)qS(O)m(CH2)t-A , -(C1-C10)alkyl, -(CH2)t-A , 1 1 1 1 -(CH2)q-(C3-C7)cycloalkyl, -(CH2)q-Y -(C1-C6)alkyl, -(CH2)q-Y -(CH2)t-A or -(CH2)q-Y -(CH2)t-(C3-C7)cycloalkyl; 45 1 wherein the alkyl and cycloalkyl groups in the definition of R are optionally independently substituted with (C1-C4) alkyl, hydroxy, (C1-C4)alkoxy, carboxyl, -CONH2, -S(O)m(C1-C6)alkyl, -CO2(C1-C4)alkyl ester, 1 H-tetrazol-5-yl or 1, 2 or 3 fluoro groups; 1 6 6 6 6 Y is O, S(O)m, -C(O)NX -, -CH=CH-, -C;C-, -N(X )C(O)-, -C(O)NX -, -C(O)O-, -OC(O)N(X )- or -OC(O)-; 50 q is 0, 1, 2, 3 or 4, with the proviso that q cannot be 0 when (CH2)q, is attached to N or O; t is 0, 1, 2 or 3; m is 1 or 2; 3 1 1 R is selected from the group consisting of A ,(C1-C10)alkyl, -(C1-C6)alkyl-A ,-(C1-C6)alkyl-(C3-C7)cycloalkyl, 1 1 1 1 -(C1-C5)alkyl-X -(C1-C5)alkyl, -(C1-C5)alkyl-X -(C0-C5)alkyl-A and -(C1-C5)alkyl-X -(C1-C5)alkyl-(C3-C7)cycloalkyl; 55 3 3 where the alkyl groups in the definition of R are optionally substituted with - S(O)m(C1-C6)alkyl, -C(O)OX ,1,2, 3, 4 or 5 independently selected halo groups or 1, 2 or 3 independently selected -OX3 groups; 1 2 2 2 2 2 2 X is O, S(O)m, -N(X )C(O)-, -C(O)N(X )-, -OC(O)-, -C(O)O-, -CX =CX -,-N(X )C(O)O, - OC(O)N(X )- or -C;C-; 2 X for each occurrence is independently hydrogen, optionally substituted (C1-C6)alkyl or optionally substituted 3 EP 1 002 802 B1 (C3-C7)cycloalkyl, where the optionally substituted (C1-C6)alkyl and optionally substituted (C3-C7)cycloalkyl in the def- 2 3 3 inition of X are optionally independently substituted with -S(O)m(C1-C6)alkyl, -C(O)OX , 1 to 5 halo groups or 1-3 OX groups; 4 4 3 R is hydrogen, (C1-C6)alkyl or (C3-C7)cycloalkyl, or R is taken together with R and the carbon atom to which 5 they are attached and form (C5-C7)cycloalkyl, (C5-C7)cycloalkenyl, a partially saturated or fully saturated 4- to 8-mem- bered ring having 1 to 4 heteroatoms independently selected from the group consisting of oxygen, sulfur and nitrogen, or R4 and R3 can be taken together to form a bicyclic ring system consisting of a partially saturated or fully saturated 5- or 6-membered ring, fused to a partially saturated, fully unsaturated or fully saturated 5- or 6-membered ring, op- tionally having 1 to 4 heteroatoms independently selected from the group consisting of nitrogen, sulfur and oxygen; 10 4 4 4 4 X is hydrogen or (C1-C6)alkyl or X is taken together with R and the nitrogen atom to which X is attached and the carbon atom to which R4 is attached and form a five to seven membered ring; R6 is a bond or 15 20 a b a b , or -(CR R )a-E-(CR R )b-; a b where the -(CR R )a- group is attached to the carbonyl carbon of the amide group of the compound of Formula I and the -(CRaRb)b group is attached to the terminal nitrogen atom of the compound of Formula I; 25 E is -O-, -S-,-CH=CH-, 30 35 40 c c which is optionally substituted with halo, hydroxy, -N(R )(R ), (C1-C6)alkyl or (C1-C6)alkoxy; a b R and R are independently hydrogen, (C1-C6)alkyl, trifluoromethyl, phenyl or substituted (C1-C6)alkyl where 45 c c c the substituents are imidazolyl, naphthyl, phenyl, indolyl, p-hydroxyphenyl, -OR , S(O)mR , C(O)OR ,(C3-C7)cy- cloalkyl, -N(Rc)(Rc), -C(O)N(Rc)(Rc); or Ra and Rb may independently be joined to one or both of R7 or E (where E is other than O, S or -CH=CH-) to form an alkylene bridge between the terminal nitrogen and the alkyl portion of the Ra or Rb and the R7 or E group, wherein the bridge contains 1 to 8 carbon atoms; or Ra and Rb may be joined to one another to form a (C3-C7)cycloalkyl; 50 c R is hydrogen or (C1-C6)alkyl; a and b are independently 0, 1, 2 or 3, with the proviso that if E is -O- or -S-, y is other than 0 or 1 and with the further proviso that if E is -CH=CH-, y is other than 0; 5 5a 1 X and X are each independently selected from the group consisting of hydrogen,
Load more

Recommended publications
  • Is Chromogranin a Prohormone? Had Only a Fraction of the Pancreastatin Potency of the Peptide Characterized by Lee E
    ~N...:.AT.;:...U=--R.;:...E_V_O_L_.~32_5 _22_J_A_NU_A_R_Y_l_98_7 _________ NEWS ANDVIEWS-------------------'--301 Peptide function small percentage of plasma chromogranin was processed to a pancreastatin-like molecule, or if native chromogranin A Is chromogranin a prohormone? had only a fraction of the pancreastatin potency of the peptide characterized by Lee E. Eiden Tatemoto et at .. It is clearly necessary to establish that the molecule isolated by IN THE 4 December issue of Nature!, K. terminal processing signal for the forma- Tatemoto et at. is indeed the substance Tatemoto and co-workers report the tion of pancreastatin from a chromogranin found at beta-cell and D-cell receptors in sequence of a newly discovered putative A-like precursor in the rat. vivo. It will be of special interest to deter- hormone, pancreastatin, which as its There is chromogranin, as well as mine if amidation is necessary for bio­ name implies inhibits insulin (and soma­ pancreastatin, immunoreactivity in the logical activity, because amidation of tostatin) secretion from the endocrine pancreas of several species, and both poly- other biologically active peptides such as pancreas. There is a striking structural peptides are present in the brain"!', consis- enkephalins seems to oc-cur differentially similarity between pancreastatin and part tent with a precursor-product relationship in central and autonomic nervous tissue, of bovine chromogranin A, whose se­ between chromogranin A and pancreas- and this differential post-translational quence was recently reported in Nature by tatin. Whether or not pancreastatin is gen- modification may be relevant to different, myself and collaborators, and independ­ erated from chromogranin A or a chromo- as yet undiscovered hormonal functions of ently in the EMBO Journal by Benedum granin A-like precursor must await the these molecules.
    [Show full text]
  • Thiol-Disulfide Exchange in Human Growth Hormone Saradha Chandrasekhar Purdue University
    Purdue University Purdue e-Pubs Open Access Dissertations Theses and Dissertations January 2015 Thiol-Disulfide Exchange in Human Growth Hormone Saradha Chandrasekhar Purdue University Follow this and additional works at: https://docs.lib.purdue.edu/open_access_dissertations Recommended Citation Chandrasekhar, Saradha, "Thiol-Disulfide Exchange in Human Growth Hormone" (2015). Open Access Dissertations. 1449. https://docs.lib.purdue.edu/open_access_dissertations/1449 This document has been made available through Purdue e-Pubs, a service of the Purdue University Libraries. Please contact [email protected] for additional information. i THIOL-DISULFIDE EXCHANGE IN HUMAN GROWTH HORMONE A Dissertation Submitted to the Faculty of Purdue University by Saradha Chandrasekhar In Partial Fulfillment of the Requirements for the Degree of Doctor of Philosophy August 2015 Purdue University West Lafayette, Indiana ii To my parents Chandrasekhar and Visalakshi & To my fiancé Niranjan iii ACKNOWLEDGEMENTS I would like to thank Dr. Elizabeth M. Topp for her tremendous support, guidance and valuable suggestions throughout. The successful completion of my PhD program would not have been possible without her constant encouragement and enthusiasm. Through the last five years, I’ve learned so much as a graduate student in her lab. My thesis committee members: Dr. Stephen R. Byrn, Dr. Gregory T. Knipp and Dr. Weiguo A. Tao, thank you for your time and for all your valuable comments during my oral preliminary exam. I would also like to thank Dr. Fred Regnier for his suggestions with the work on human growth hormone. I am grateful to all my lab members and friends for their assistance and support. I would like to especially thank Dr.
    [Show full text]
  • A Process for Producing Human Growth Hormone
    Patentamt JEuropaischesEuropean Patent Office (in Publication number: 0 217 814 Office europeen des brevets B1 EUROPEAN PATENT SPECIFICATION Date of publication of patent specification: 16.05.90 int.ci.5: C 12 P 21/06, C 12 N 15/00 Application number: 86901361.5 Date of filing: 06.02.86 International application number: PCT/DK86/00014 International publication number: WO 86/04609 14.08.86 Gazette 86/18 A PROCESS FOR PRODUCING HUMAN GROWTH HORMONE. (§) Priority: 07.02.85 DK 556/85 Proprietor: NOVO-NORDISK A/S Novo Alle DK-2880 Bagsvaerd (DK) Date of publication of application: 15.04.87 Bulletin 87/16 Inventor: ANDERSEN, Henrik, Dalboge Ordrupvej 1 12 B Publication of the grant of the patent: DK-2920 Charlottenlund (DK) 16.05.90 Bulletin 90/20 Inventor: PEDERSEN, John Kajerodvaenge 35 DK-3460 Birkero /d (DK) Designated Contracting States: Inventor: CHRISTENSEN, Thorkild AT BE CH DE FR GB IT LI LU NL SE Bellisvej 55 DK-3450Allerod(DK) Inventor: HANSEN, Jorli, Winnie References cited: Kloverhoj20 EP-A-0020290 DK-2600Glostrup(DK) EP-A-0089626 Inventor: JESSEN, Torben, Ehlern WO-A-84/02351 Kalundborgvej 216 US-A-4543329 DK-4300Holbaek(DK) Chemical Abstracts, vol. 77, 1972, Abstract no. 2289q, Calluhan et al, Fed. Proc. Fed. Amer, Coc. Representative: von Kreisler, Alek, Dipl.-Chem. Exp. Biol. 1972 31(3), 1105-13 (Eng). etal 00 Deichmannhaus am Hauptbahnhof Chemical Abstracts, vol. 76, 1972, Abstract no. D-5000 Koln 1 (DE) 83215s, Lindley et al. Biochem J. 1972. 126(3), 683-5(Eng). O Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted.
    [Show full text]
  • Evidence That the Major Degradation Product of Glucose-Dependent Insulinotropic Polypeptide, GIP(3–42), Is a GIP Receptor Antagonist in Vivo
    525 Evidence that the major degradation product of glucose-dependent insulinotropic polypeptide, GIP(3–42), is a GIP receptor antagonist in vivo V A Gault, J C Parker, P Harriott1, P R Flatt and F P M O’Harte School of Biomedical Sciences, University of Ulster, Cromore Road, Coleraine, N Ireland BT52 1SA, UK 1Centre for Peptide and Protein Engineering, School of Biology and Biochemistry, The Queen’s University of Belfast, Medical Biology Centre, Belfast, N Ireland BT9 7BL, UK (Requests for offprints should be addressed to V A Gault; Email: [email protected]) Abstract The incretin hormone glucose-dependent insulinotropic was significantly less potent at stimulating insulin secretion polypeptide (GIP) is rapidly degraded in the circulation (1·9- to 3·2-fold; P<0·001), compared with native GIP by dipeptidyl peptidase IV forming the N-terminally and significantly inhibited GIP-stimulated (107 M) truncated peptide GIP(3–42). The present study exam- insulin secretion with maximal inhibition (48·86·2%; ined the biological activity of this abundant circulating P<0·001) observed at 107 M. In (ob/ob) mice, admin- fragment peptide to establish its possible role in GIP istration of GIP(3–42) significantly inhibited GIP- action. Human GIP and GIP(3–42) were synthesised stimulated insulin release (2·1-fold decrease; P<0·001) and by Fmoc solid-phase peptide synthesis, purified by exaggerated the glycaemic excursion (1·4-fold; P<0·001) HPLC and characterised by electrospray ionisation-mass induced by a conjoint glucose load. These data indicate spectrometry. In GIP receptor-transfected Chinese ham- that the N-terminally truncated GIP(3–42) fragment acts ster lung fibroblasts, GIP(3–42) dose dependently inhib- as a GIP receptor antagonist, moderating the insulin ited GIP-stimulated (107 M) cAMP production (up to secreting and metabolic actions of GIP in vivo.
    [Show full text]
  • V1-Vasopressin Antagonists
    Europaisches Patentamt ® 0 1 82 626 � European Patent Office © Publication number: Office europeen des brevets A2 © EUROPEAN PATENT APPLICATION © Application number: 85308325.1 © Int. CI.4: C07K 7/06 , C07K 7/1 6 , A61 K 37/02 (g)rs Date of filing: 15.11.85 ® Priority: 21.11.84 US 673828 © Applicant: SMITHKLINE BECKM AN CORPORATION P.O. Box 7929 1 Franklin Plaza © Date of publication of application: Philadelphia Pennsylvania 191 01 (US) 28.05.86 Bulletin 86/22 © Inventor: Ali, Fadia Elfehail © Designated Contracting States: 5 Green Acre Drive, N. AT BE CH DE FR GB IT LI LU NL SE Cherry Hill New Jersey 08003(US) Inventor: Huffman, William Francis 40 Crest Avenue Malvern Pennsylvania 19355(US) © Representative: Waters, David Martin, Dr. et al Smith Kline & French Laboratories Ltd. Patent De- partment Mundells Welwyn Garden City Hertfordshire AL7 1EY(GB) © V1 -vasopressin antagonists. Compounds having the formula: in which: or a pharmaceutically acceptable salt thereof, which have V,-vasopressin antagonist activity and which are useful in the treatment of hypertension, shock and cardiac insuffi- P is Phe, Ile, Phe(4'-Alk), Tyr or Tyr(Alk); ciency. X is a D or L isomer of Val, Nva, Leu, Ile, Pba, Phe, Phe(4'-Alk), Trp, Nle, Cha, Abu, Met, Chg, Tyr or Tyr(Alk); Y is Val, Ile, Abu, Ala, Chg, Gln, Lys, Cha, Thr, Nle, Phe, Leu or Gly; Z is a D or L isomer of Arg, Harg, Leu, Lys or Orn; A is Gly(NH,), Gly, Gly(NH-Alk), OH, NH, or NHAlk; and R is, each, hydrogen or methyl; This invention relates to cyclic peptides which have studied, the β,β-diethyl and β,β-cyclopentamethylene pro- vasopressin (VSP) antagonist activity.
    [Show full text]
  • Page 1 of 30 Food & Function
    Food & Function Accepted Manuscript This is an Accepted Manuscript, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication. Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this Accepted Manuscript with the edited and formatted Advance Article as soon as it is available. You can find more information about Accepted Manuscripts in the Information for Authors. Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal’s standard Terms & Conditions and the Ethical guidelines still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this Accepted Manuscript or any consequences arising from the use of any information it contains. www.rsc.org/foodfunction Page 1 of 30 Food & Function Novelty of work In vitro transport of β-CM7 is limited by rapid hydrolysis into three peptide metabolites that transport at variable rates. 3.0 * 2.5 * * 2.0 * 1.5 1.0 * Manuscript Ratio to basal CCK-8 secretion CCK-8 basal to Ratio 0.5 0.0 M M M M M M M M M M M M M 500 250 125 500 250 125 500 250 125 1000 1000 1000 Fig. 8. Secretion of cholecystokinin[26-33] (CCK-8) by STC-1 cells in response to decreasing Accepted concentrations of YL and β-CM7 , compared to HBSS (basal) control .
    [Show full text]
  • Effect of Homochirality of Dipeptide to Polymers' Degradation
    polymers Article Effect of Homochirality of Dipeptide to Polymers’ Degradation Xinqiang Xu 1,2, Fuyan He 1,2, Wenke Yang 1,2 and Jinshui Yao 1,2,* 1 School of Materials Science & Engineering, Qilu University of Technology (Shandong Academy of Sciences), Jinan 250353, China; [email protected] (X.X.); [email protected] (F.H.); [email protected] (W.Y.) 2 Shandong Provincial Key Laboratory of Processing & Testing Technology of Glass and Functional Ceramics, Jinan 250353, China * Correspondence: [email protected] Received: 31 August 2020; Accepted: 18 September 2020; Published: 22 September 2020 Abstract: As natural polymer materials, proteins are readily biodegradable, interestingly, the synthetic polyamides (PAs) that are based on the same amide bonds (also called peptide bonds in proteins) are barely degradable. Whether did the chirality and configuration of the amino acids play an important role. By using different configuration of amino acids, 4 types of polyamide-imides (PAIs) containing dipeptides of LL, DL, LD, and DD configurations, respectively, were synthesized. It was found that the PAIs based on natural LL configuration of dipeptide structure are much more readily biodegradable than those based on non-natural LD, DL, and DD configuration of dipeptides. It was confirmed that the natural L-configuration of amino acids play a critical role in degradability of proteins. And it also suggested that different type and amount of peptide fragments can be introduced in polymer to create series of polymer materials that can be biodegraded at controllable speed. Keywords: chiral amino acids; dipeptide; polyamide-imides; biodegradability 1. Introduction With the growing problem of white pollution, degradable polymer materials are attracting more and more attention because polymer materials that can be degraded at controllable speed could be used in every kind of fields [1–6].
    [Show full text]
  • Gastrin-Releasing Peptide (Grp)/Bombesin-Like Immunoreactivity in the Neurons and Paraneurons of the Gut and Lung
    Biomedical Research 4 (1) 93-104, 1983 GASTRIN-RELEASING PEPTIDE (GRP)/BOMBESIN-LIKE IMMUNOREACTIVITY IN THE NEURONS AND PARANEURONS OF THE GUT AND LUNG TOSHIHIKO IWANAGA Department of Anatomy, Niigata University School of Medicine, Niigata 951, Japan ABSTRACT Gastrin-releasing peptide (GRP)/bombesin-like immunoreactivities in the gut and lung were investigated with an immunocytochemical method using antisera showing different specificity for GRP-related peptides and bombesin. GRP-like, but not bombesin-like, immunoreactivity in the gut of birds and frogs was contained in the endocrine cells, which were restricted mainly to the oxyntic mucosa. On the other hand, GRP immunoreactivity in the rat and swine gut was contained in the nerve fibers distributed in the gastric mucosa and in the submucosal and myenteric plex- uses of the gut wall. In the lungs of human fetuses, the endocrine cells, solitary or gathered in groups, were immunoreactive to the GRP antisera. These endocrine cells and nerve fibers in the gut and lung showed the same immunoreactivity to two GRP antisera, but not to a bombesin-specific antiserum. This suggests that the bombesin- like immunoreactivities reported in the previous studies may be due to the existence of GRP or GRP-related peptides. Electron microscopic immunocytochemistry revealed that the GRP-like immunoreactivity was localized in the cytoplasmic gran- ules of the pulmonary endocrine cells and in the dense-cored vesicles of the gut nerve fibers. Bombesin is a tetradecapeptide isolated from the resides in the C-terminal portion of the molecule skin of Bombina bombina and Bombina variegara (17). Moreover, a heptacosapeptide having (1).
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,097.590 B2 Pinel Et Al
    USO08097590B2 (12) United States Patent (10) Patent No.: US 8,097.590 B2 Pinel et al. (45) Date of Patent: Jan. 17, 2012 (54) o-MSH-ANTAGONIST DIPEPTIDE FOREIGN PATENT DOCUMENTS CONUGATES EP O 389 95.0 A1 10, 1990 EP O 669938 B1 9, 1995 (75) Inventors: Anne-Marie Pinel, Toulouse (FR): E. : 29: R 1928 Pascal Verdie, Saint Mathieu de Treviers EP 1174 437 A1 1, 2002 (FR); Pascaline Dubs, Montpellier (FR): FR 1327363 5, 1962 Jean Martinez, Caux (FR); Gilles FR 2805744 A1 9, 2001 Subra, Juvignac (FR) FR 2810 323 A1 12/2001 s GB 1 OOO 897 8, 1965 (73) Assignees: Centre National de la Recherche W. W. 2.95. A. 3E Scientifique (CNRS), Paris (FR): WO WO 98.25584 A1 6, 1998 Institut Europeen de Biologie W. W. 9.3. A. 358: Cellulaire, Ramonville St. Agne (FR): WO WO O2/O85925 A2 10, 2002 Universite de Montpellier I, WO WO 03/064.458 A2 8, 2003 Montpellier (FR); Universite de WO WOO3,O95474 A2 11/2003 Montpellier II, Montpellier (FR) WO WO 2004/099237 A1 11, 2004 WO WO 2004/110341 A2 12/2004 (*) Notice: Subject to any disclaimer, the term of this WO WO 2005,116068 A1 12/2005 patent is extended or adjusted under 35 OTHER PUBLICATIONS U.S.C. 154(b) by 1143 days. Stverteczky et al., Acta Chimica Academiae Scientiarum (21) Appl. No.: 11/596,286 Hungaricae, 1975, vol. 87, No. 3, pp. 269-283.* Baumann et al., “Specificity of O-chyrinotrypsin dipeptide Sub (22) PCT Filed: May 10, 2005 strates.” FEBS Letters, Jun.
    [Show full text]
  • United States Patent Office Patented June 19, 1973
    3,740,385 United States Patent Office Patented June 19, 1973 1. 2 R-His-Ser-Asp-Gly 3,740,385 !-- N-TERMINAL DERVATIVES OF SECRETN Thr-Phe-Thr-Ser-Glu-Leu-Ser-Arg Miguel Angel Ondetti, 265 Hamlin Road, Leu-Arg-Asp-Ser-Ala-Arg-Leu-Glu(NH2)- North Brunswick, N.J. 08902 No Drawing. Continuation-in-part of abandoned applica Arg-Leu-Leu-Glu(NH2)-Gly-Leu-Val-NH2 tion Ser. No. 827,962, May 26, 1969. This application J. May 7, 1970, Ser. No. 35,598 R1-secretin Int. C. C07c 103/52, C07g 7/00 U.S. C. 260-112.5 6 Claims wherein R1 is a carboxylic acid, an amino acid, or a 10 dipeptide. The above equation takes into consideration that the ABSTRACT OF THE DISCLOSURE proper protection of the required moieties is followed. Disclosed herein are novel N-terminal derivatives of In addition when an acid is utilized, the desired acid the peptide secretin, intermediates thereof and a process may be reacted with secretin according to the equation: for their preparation. The secretin derivative of this in 5 vention are useful as antacids in hyperacidic conditions R2-COX--Secretin->R-CO-Secretin of the stomach and duodenum. wherein R2 is lower alkyl (e.g., methyl, ethyl, isopropyl, RELATED APPLICATION hexyl), aryl (e.g., phenyl or naphthyl), substituted phenyl 20 (e.g., o-chlorophenyl, p-ethylphenyl, m-trifluoromethyl This application is a continuation-in-part of my co phenyl, m-nitrophenyl), aralkyl (e.g., benzyl or phen pending application Ser. No. 827,962 filed May 26, 1969, ethyl), lower alkoxy (e.g., methoxy, ethoxy, butyloxy or now abandoned.
    [Show full text]
  • Development of Dipeptide Transport in the Intestinal Mucosa of Rabbits
    Pediatr. Res. 16: 99-103 (1982) Development of Dipeptide Transport in the Intestinal Mucosa of Rabbits STEFAN0 GUANDALINI'32' AND ARMIDO RUBINO Child Health Institute, 2nd School of Medicine, University of Naples, Italy Summary other hand, they can also be hydrolyzed at the brush border membrane, with-subsequent entjof the released amino acids. The uptake of 0.5 mM glycyl-L-proline (Gly-Pro), a substrate We had previously shown (24) that both ways do occur also in which has affinity for the dipeptide specific carrier system and is in the small intestine of the newborn rabbit, the transport of intact not hydrolyzed in the brush border, was studied vitro in jejunum dipeptide being quantitatively approximately as important as the and ileum of rabbits from the 25th day of gestational age into other pathway. We thus moved to investigate, in the developing adulthood. For comparison, uptake of 0.5 mM glycine was studied rabbit, the carrier system for dipeptides, with these major aims: too. Results show that influx of Gly-Pro is present from the (1) provide a biologic characterization of the system as for sub- earliest age studied and show a steep prenatal increase and peaks straie specificity, ~a dependence and kinetic constants; (2) define f at birth, with values, in the newborn jejunum, of 45.2 3.3 pmoles/ its developmental pattern as compared to that of the uptake of a ghr (mean + S.E.). Thereafter, the uptake slowly declines toward free neutral amino acid, as to provide an ontogenetic basis for the the adult level of 3.8 f 0.5 pmoles/ghr.
    [Show full text]
  • Fish Derived Bio-Active Peptides and Their Metabolic Effects Balık Kaynaklı Biyo-Aktif Peptidler Ve Metabolik Etkileri
    http://www.egejfas.org Su Ürünleri Dergisi (2015 Ege J Fish Aqua Sci 32(4): 217-223 (2015) DOI: 10.12714/egejfas.2015.32.4.08 REVIEW DERLEME Fish derived bio-active peptides and their metabolic effects Balık kaynaklı biyo-aktif peptidler ve metabolik etkileri Can Altınelataman1* • Anna Torkova2 • Mikhail Tsentalovich2 1Ege University, Faculty of Fisheries, 35100, Bornova, İzmir, Turkey 2Federal State Institution, Federal Research Centre, Fundamentals of Biotechnology of the Russian Academy of Sciences, Biochemistry Institute of Russian Academy of Sciences, Moscow, Russia *Corresponding Author: [email protected] How to cite this paper: Altınelataman, C., Torkova, A., Tsentalovich, M., 2015. Fish derived bio-active peptides and their metabolic effects. Ege J Fish Aqua Sci 32(4): 217-223. doi: 10.12714/egejfas.2015.32.4.08 Özet: Diğer tüm organizmalar gibi, balıklar da, araştırmalarda antimikrobiyal, antihipertensif, antioksidan ve antitümör aktivitelerine odaklanılan bio-aktif bileşiklerin zengin kaynağıdırlar. Bunlar, sadece yüksek besin değeri nedeniyle değil, özellikle son yirmi yılda geliştirilen analitik yöntemlerle elde edilen peptidleri açısından da kullanılabilirler. Akuatik canlılar dünya üzerinde en fazla tür sayısına sahiptir, dolayısıyla bunlardan bio-aktif peptidlerin eldesi diğerlerine göre oldukça olasıdır ve bu, önceki çalışmalarda açıkça ortaya konmuştur. Doğal peptidler ve uzun zincirli polipeptidlerden uygun enzimatik yöntemlerle elde edilen peptidler tıp alanında yeni ufuklar açabilirler. Anahtar kelimeler: Balık, peptidler, bio-aktif, metabolik etki, sağlık Abstract: Like many other organisms, fishes are also rich sources of bio-active compounds which were well studied by research focused on their antimicrobial, antihypertensive, antioxidant and antitumor activities. They can be used not only for good nutritional value, but also for peptides obtained with analytic processes that were developed in last decades.
    [Show full text]